New agents, new rashes: an update on skin complications from cancer chemotherapy

Area of Science:

• Oncology
• Dermatology
• Clinical Pharmacology

Background:

• Recent advancements in cancer therapy have introduced novel antineoplastic agents.
• A significant proportion of these new drugs are associated with dermatological adverse events, notably skin rash.
• Rash is a common toxicity observed with epidermal growth factor receptor inhibitors, impacting cancer patient care.

Purpose of the Study:

• To review the occurrence and characteristics of rash associated with recently approved cancer drugs.
• To specifically discuss rash in the context of epidermal growth factor receptor inhibitors.
• To explore challenges in designing clinical trials for managing drug-induced rash.

Main Methods:

• Literature review of recent antineoplastic drug approvals and associated adverse events.
• Focused analysis of studies reporting rash with epidermal growth factor receptor inhibitors.
• Discussion of clinical trial design considerations for rash palliation.

Main Results:

• Several new antineoplastic agents have been approved in the last five years.
• Skin rash is a frequent adverse event for many of these new drugs.
• Rash is a primary toxicity for epidermal growth factor receptor inhibitors.

Conclusions:

• Understanding drug-induced rash is crucial for managing patients on new cancer therapies.
• Effective strategies for rash palliation are needed to improve patient compliance and quality of life.
• Further research and optimized clinical trial designs are necessary to address rash management in oncology.